Join to View Full Profile
1650 Orleans StCRB1-Room 186Baltimore, MD 21287
Phone+1 410-955-8893
Dr. Nakazawa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Medical Oncology, 2022- Johns Hopkins UniversityResidency, Internal Medicine, 2019 - 2022
University of Kentucky College of MedicineClass of 2019
Certifications & Licensure
MD State Medical License 2022 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors.Chester Kao, Soren Charmsaz, Hua-Ling Tsai, Khaled Aziz, Daniel H Shu
Nature Communications. 2025-04-21 - Anti-CTLA4 therapy leads to early expansion of a peripheral Th17 population and induction of Th1 cytokines.Mari Nakazawa, Soren Charmsaz, Elsa Hallab, Mike Fang, Chester Kao
Cancer Immunology Research. 2025-03-27 - Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.Stephanie L Alden, Soren Charmsaz, Howard L Li, Hua-Ling Tsai, Ludmila Danilova
Journal for Immunotherapy of Cancer. 2025-01-19
Press Mentions
Neoadjuvant Immunotherapy for Liver Cancer: Shrinking Tumors, Growing ResponsesOctober 18th, 2024- Outcomes Similar for Neoadjuvant ICI-Based Therapy, Upfront Surgery for Liver CancerAugust 23rd, 2024
- Immunotherapy Prior to Surgery May Improve Outcomes for High-Risk Liver Cancer PatientsAugust 21st, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
